Background
==========

Patients with congenital heart disease (CHD) with significant untreated left-to-right shunt lesions are at risk of developing pulmonary arterial hypertension (PAH). Eisenmenger's syndrome (ES), a clinical condition with an initial large systemic-to-pulmonary shunt that induces severe pulmonary vascular disease \[[@B1]\], represents the most advanced form of PAH-CHD and is characterised by reversed pulmonary-to-systemic (right-to-left) shunt and central cyanosis. The Euro Heart Survey on adult CHD (a retrospective cohort study with a 5-year follow-up) reported PAH in 531 (28%) patients \[[@B2]\], while a Dutch registry showed a PAH prevalence of 4.2% in 5970 adult patients with CHD \[[@B3]\]. In the latter registry, 58% of patients with a septal defect who developed PAH had ES.

Patients with Down's syndrome represent an important subgroup in the ES population as they are considered to be at risk of PAH earlier than patients without Down's syndrome and also have worse functional capacity \[[@B4]\]. This is probably due to different pathogenetic factors between patients with and without Down's syndrome \[[@B5]\]. Down's syndrome has been estimated to occur in ≈ 1.1/1000 adults in the UK \[[@B6]\] and ≈ 1/732 infants in the USA \[[@B7]\]. However, there is some evidence that prevalence varies between different racial and ethnic groups \[[@B8]\]. The association between Down's syndrome and CHD has been well established \[[@B9]\]. The prevalence of CHD in patients with Down's syndrome is 40--60% \[[@B10],[@B11]\] and the types of malformation that are most commonly associated with trisomy 21 are the atrio-ventricular and ventricular septal defects (AVSD and VSD), which together account for 76% of all CHD seen in patients with Down's syndrome \[[@B12]\]. Although AVSD is frequently reported as the most common cardiac defect, there is some evidence that this varies according to sex and ethnicity \[[@B8],[@B10]-[@B15]\].

Treatment options for ES patients are limited and the Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) study, which demonstrated the efficacy and tolerability of the endothelin receptor antagonist, bosentan, is the only placebo-controlled study in this population to date \[[@B16]\]. Data in patients with Down's syndrome are even more limited, with the only evidence of the efficacy of PAH-specific therapies in this population being from small, or single-centre studies \[[@B17]-[@B22]\].

The aim of the present study was to evaluate the long-term efficacy of bosentan in adult ES patients with Down's syndrome.

Methods
=======

This was a retrospective analysis of data collected from consecutive adult ES patients with Down's syndrome (mild cognitive impairment verified by the Wechsler Adult Intelligence Scale -- Revised \[[@B23]\]) treated with bosentan at our centre. Permission to collect data prospectively was obtained from the parents or the legal tutor prior to entering the study. Adults with a diagnosis of ES confirmed by right heart catheterization, in World Health Organization (WHO) functional class III between May 2007 and April 2008 were included. The final follow-up visits took place between January and February 2012.

Clinical evaluation at baseline included: medical history, WHO functional class, resting transcutaneous arterial oxygen saturation (SaO~2~) for 30 minutes and liver enzymes (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\]). Exercise capacity was evaluated using a 6-minute walk test (6MWT) where the following variables were assessed: rest and peak exercise transcutaneous oxygen saturation (SpO~2~), heart rate, systemic blood pressure, 6-minute walk distance (6MWD) and Borg dyspnoea index. Several days prior to the 6MWT patients were educated about the 6MWT. The test was performed under the same environmental conditions and at approximately the same time of the day (± 1 hour) in all patients and physicians observed the patients' attention and approach to the 6MWT.

A complete Doppler echocardiography (echo) study was conducted in each patient according to current European guidelines \[[@B24]\]. The following variables were assessed: right ventricular (RV) systolic pressure from tricuspid regurgitation (TR) jets, maximal velocity from pulmonary regurgitation jets, acceleration/ejection time ratio (AcT/ET) from the pulmonary flow, direction and maximal velocity across the VSD.

Bosentan was administered at a starting dose of 62.5 mg twice daily immediately after the baseline assessment. The dose was increased to the target dose of 125 mg twice daily 4 weeks later. Follow-up assessments were conducted in all patients at Months 3, 6, 9 and 12 of bosentan therapy and every 6 months, thereafter. Assessments included measurement of SpO~2~, blood tests, 6MWT and Doppler echo examination.

Statistical analysis
--------------------

Continuous variables are presented as means with standard deviations and ranges, categorical data are presented as counts and percentages. Statistical analyses were performed using the Wilcoxon signed-rank test. Variables were analysed at baseline and at sequential follow-up visits. A p value \< 0.05 was considered as the level of significance.

Results
=======

In total, seven adults (four males, three females) with Down's syndrome and ES were included. Their mean age was 29.6 ± 11.2 years, all patients were in WHO functional class III and had a VSD (two with associated mitral valve regurgitation). None of the patients had received previous PAH-specific therapy. Oxygen therapy was required for 10 hours/day by two patients. Concomitant therapy was required by six patients (thyroid hormones \[n = 6\], allopurinol \[n = 3\], ticlopidine \[n = 1\]). Baseline SaO~2~ at rest was 81.7 ± 6.6% (range 71--88%).

Patients were followed up for a mean period of 52.2 ± 3.9 months (range 46.0--55.5 months). All patients remained on bosentan monotherapy until the end of the study.

Clinical assessment
-------------------

In comparison with the baseline evaluation, at the final follow-up assessment, there was an improvement to WHO functional class II in one patient. Mean SaO~2~ at rest increased from 81.7 ± 6.6% (range 71--88%) at baseline to 89.0 ± 3% (range 87--92%) (*P* \< 0.02) at Month 24 and 88.3 ± 3.2% (range 84--93%) at the final follow-up assessment (p \< 0.05). AST and ALT levels increased slightly in one patient, but remained lower than twice the upper limit of normal.

The mean 6MWD increased from 199.6 ± 69.1 metres at the baseline assessment to 291.9 ± 115 metres at Month 24 (*P* = 0.016) and 303.7 ± 99.9 metres at the final follow-up assessment (*P* = 0.016). The mean SpO~2~ at the end of the 6MWT was 61.6 ± 7.6% at the baseline assessment, 74.3 ± 5.4% at the Month 24 assessment (*P* = 0.016) and 74.7 ± 6.2% at the final follow-up assessments (p = 0.016). Borg dyspnoea index was 3.6 ± 1.4 at baseline and 2.4 ± 1.1 at the final follow-up assessment (not significant). Diastolic blood pressure decreased from 80.0 ± 5.8 mmHg (range: 70--90 mmHg) at the baseline assessment to 68.6 ± 4.8 mmHg (range: 60--75 mmHg) at the final assessment (Table [1](#T1){ref-type="table"}, and Figure [1](#F1){ref-type="fig"}).

![**6-minute walk distance (6MWD), peak exercise transcutaneous arterial oxygen saturation (SpO**~**2**~**) before and at the end of the 6-minute walk test at baseline and a. Month 24 and b. Last visit**](1471-2261-13-74-1){#F1}

###### 

Effect of bosentan on blood pressure, exercise capacity and blood oxygen saturation

  **Parameter, mean ± SD (p value)**   **Baseline**   **Month 3**               **Month 6**               **Month 9**^**b**^         **Month 12**           **Month 18**            **Month 24**            **Final follow-up**^**a**^
  ------------------------------------ -------------- ------------------------- ------------------------- -------------------------- ---------------------- ----------------------- ----------------------- ----------------------------
  SBP (mmHg)                           125.7 ± 14.0   105.0 ± 11.8^b^ (0.063)   111.7 ± 9.8^b^ (0.125)    111.7 ± 5.2^b^ (0.094)     114.3 ± 13.7 (0.250)   113.7 ± 9.6 (0.188)     106.4 ± 7.5 (0.063)     108.6 ± 9.0 (0.094)
  DBP (mmHg)                           80.0 ± 5.8     74.2 ± 8.6^b^ (0.125)     79.2 ± 8.0^b^ (1.000)     73.3 ± 11.7^b^ (0.281)     69.3 ± 8.4 (0.031)     73.6 ± 8.5 (0.250)      68.9 ± 7.8 (0.063)      68.6 ± 4.8 (0.031)
  6MWD (m)                             199.6 ± 69.1   291.7 ± 73.1^b^ (0.063)   260.7 ± 60.2^b^ (0.063)   292.3 ± 112.7^b^ (0.031)   301.6 ± 88.7 (0.016)   317.4 ± 105.8 (0.016)   291.9 ± 115.4 (0.016)   303.7 ± 99.9 (0.016)
  SaO~2~ (%) at rest                   81.7 ± 6.6     87.2 ± 5.6^b^ (0.063)     88.4 ± 2.7 (0.031)        89.3 ± 2.5^b^ (0.031)      89.0 ± 2.5 (0.016)     87.9 ± 4.5 (0.109)      89.3 ± 1.8 (0.031)      88.3 ± 3.2 (0.016)
  SpO~2~ (%) before 6MWT               81.0 ± 6.6     87.0 ± 6.4^b^ (0.094)     87.2 ± 3.8^b^ (0.031)     89.3 ± 1.0^b^ (0.031)      88.7 ± 3.1 (0.031)     88.6 ± 5.3 (0.047)      89.9 ± 1.8 (0.016)      88.0 ± 3.3 (0.016)
  SpO~2~ (%) at end of 6MWT            61.6 ± 7.6     68.2 ± 9.3^b^ (0.250)     67.7 ± 3.0^b^ (0.063)     72.5 ± 6.2^b^ (0.031)      70.6 ± 10.1 (0.078)    71.0 ± 7.5 (0.016)      74.3 ± 5.4 (0.016)      74.7 ± 6.2 (0.016)
  Borg dyspnoea index                  3.6 ± 1.4      2.3 ± 1.2^b^ (0.063)      2.8 ± 1.5^c^ (0.250)      3.2 ± 1.2^b^ (1.000)       2.1 ± 1.2 (0.016)      2.9 ± 1.8 (0.313)       3.7 ± 2.9 (1.000)       2.4 ± 1.1 (0.250)

SBP: systolic blood pressure; DBP: diastolic blood pressure; 6MWT: 6-minute walk test; SaO~2~: transcutaneous arterial oxygen saturation; SpO~2~: peak exercise transcutaneous arterial oxygen saturation.

^a^Wilcoxon signed-rank test (two-sided) on change from baseline statistically significant (p \< 0.05).

^b^n = 6 due to missing data.

^c^n = 5 due to missing data.

Doppler echo assessment
-----------------------

Baseline echo parameters are shown in Table [2](#T2){ref-type="table"}. At final follow-up there was a significant change in AcT (p \< 0.0156) and AcT/ET ratio (p \< 0.0156) from the pulmonary flow. RV and left ventricular systolic functions remained stable during follow-up (Table [2](#T2){ref-type="table"}).

###### 

Effect of treatment with bosentan on echocardiographic parameters

  **Parameter**                       **Baseline**   **Final follow-up**   ***P*value**^**a**^
  ----------------------------------- -------------- --------------------- ---------------------
  RVSP from TR (mmHg) (n = 4)         94.0 ± 13.4    85.5 ± 7.6            0.3750
  Peak velocity of PR (m/s) (n = 2)   4.00 ± 0.14    4.05 ± 0.07           1.0000
  AcT (m/s)                           62.9 ± 11.6    83.0 ± 9.6            0.0156
  AcT/ET                              0.24 ± 0.04    0.30 ± 0.02           0.0156

RVSP: right ventricular systolic pressure; TR: tricuspid regurgitation; PR: pulmonary regurgitation; AcT: acceleration time; AcT/ET: acceleration/ejection time ratio; ^a^Wilcoxon signed-rank test.

Discussion
==========

In this long-term analysis, treatment of adult ES patients with Down's syndrome with bosentan for a mean period of more than 4 years resulted in significant initial improvements in SaO~2~ at rest and 6MWD that were sustained during follow-up. Treatment options for patients with ES are limited, with the BREATHE-5 study being the only placebo-controlled study in this population \[[@B16]\]. It demonstrated that bosentan significantly reduced pulmonary vascular resistance index and mean pulmonary arterial pressure and significantly improved 6MWD in ES patients in WHO functional class III. Safety (change from baseline in SpO~2~) was the primary endpoint in the BREATHE-5 study and the authors demonstrated that bosentan did not worsen oxygen saturation. Data from a number of studies, including the current study, have since confirmed these benefits in the longer term in patients with PAH-CHD and specifically in patients with ES \[[@B19],[@B21],[@B25]-[@B28]\]. In addition, PAH-specific therapy has been shown to significantly lower the all-cause mortality rate in a large population of ES patients, providing strong conceptual support for treatment of all ES patients with PAH-specific therapy \[[@B29]\].

Patients with Down's syndrome are at risk of developing PAH earlier than patients without Down's syndrome and have worse functional capacity \[[@B1]\]. Both these factors are associated with poor long-term outcome \[[@B4],[@B5],[@B29]-[@B31]\]. There are no randomized controlled trials in this subpopulation of PAH-CHD patients. The results of our long-term analysis support data from previous open-label studies, which have demonstrated the efficacy of bosentan in ES patients with Down's syndrome \[[@B19]-[@B21]\], and suggest that up to 4 years' treatment can be beneficial in these patients. A previous study has shown that there was no significant difference in mortality between ES patients with and without Down's syndrome after 4 years of bosentan treatment \[[@B21]\]. Similarly, no differences in the efficacy of bosentan between PAH-CHD patients with and without Down's syndrome in a 12-month study have been reported, with both groups showing significant improvements in 6MWD, WHO functional class and haemodynamics \[[@B20]\].

The validity of the 6MWT in patients with Down's syndrome has been questioned as it has been reported that level of intellectual disability is an independent factor for 6MWD \[[@B32]\]. Vis and coworkers showed that there was a significant difference in mean 6MWD between the group with a mild/moderate level of intellectual disability (318 ± 92 metres) and the group with a severe/profound level of intellectual disability (195 ± 84 metres). In our study, patients had a low level of intellectual disability; however, 6MWD was in the range seen in patients with severe intellectual disability in the Vis study. Importantly in the current study, patients achieved a significant increase in 6MWD with long-term bosentan therapy. These findings are similar to those from a recently published series of patients which demonstrated that 6MWD increased in patients with Down's syndrome during the first 12 months of bosentan therapy -- achieving early significance -- and this improvement from baseline was maintained during a further 24 months of therapy \[[@B18]\]. Although it has been shown that there is no discrepancy between improvement in 6MWD and haemodynamic parameters in patients with Down's syndrome \[[@B20]\], it is clear from the contrasting results from published small studies that we still need to understand more about use of the 6MWT in this population. Consequently, although there is some debate about the most appropriate assessment in this patient population, evidence of bosentan efficacy has been demonstrated. Based on our experience, we believe that patients' compliance -- in the presence of mild intellectual disability -- is sufficient to guarantee a reliable result as confirmed by the assessment of objective parameters.

In the present study we did not perform an invasive evaluation such as right heart catheterization during follow-up visits. However, several studies report a high correlation (0.57 to 0.93) between echocardiographic and haemodynamic measurements of pulmonary arterial systolic pressure and, therefore, the echocardiographic assessment used in the current analysis provides valid information \[[@B33]-[@B35]\]. Baseline values of TR velocity and pulmonary arterial systolic pressure in the patients included in the current study were higher than those associated with the presence of pulmonary hypertension as specified in the current guidelines \[[@B24]\]. Additional variables to confirm the presence of pulmonary hypertension were also included in accordance with the guidelines (i.e. increased pulmonary valve regurgitation velocity, shortened acceleration time of RV ejection into the pulmonary artery, increased dimensions of the right heart chambers, abnormal shape and function of the interventricular septum and increased right ventricular wall thickness and pericardial effusion were demonstrated).

WHO functional class remained stable in the majority of patients during treatment, with an improvement in functional class being achieved by one patient. In the BREATHE-5 study, pulmonary vascular resistance index increased in the placebo arm during the 16-week study period, demonstrating the progressive nature of ES \[[@B16]\]. As a result, the maintenance of patients in WHO functional class III during prolonged bosentan therapy is encouraging.

The long-term results from this study provide confirmation of the significant improvement in exercise capacity and SpO~2~ in ES patients with Down's syndrome seen in previous studies \[[@B17],[@B20],[@B21]\]. Additionally, this improvement was quick and progressive (in the first 6 months) and was then stable for up to 48 months.

Our study has some limitations, specifically the small number of patients and the lack of a placebo-controlled group and that data are only confirmed by echocardiography and not by right heart catheterization. However, it represents, with few other studies, one of the largest series of ES patients with Down's syndrome treated with bosentan for an extended period. As a result the significant and stable increase in 6MWD and oxygen saturation are of clinical relevance.

Conclusion
==========

Long-term treatment with bosentan in adult ES patients with Down's syndrome was well tolerated and significantly improved oxygen saturation and 6MWD. Our study confirms that the presence of Down's syndrome does not affect the response to oral bosentan therapy in adult ES patients.
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